期刊
ARTHRITIS & RHEUMATOLOGY
卷 66, 期 9, 页码 2570-2579出版社
WILEY-BLACKWELL
DOI: 10.1002/art.38699
关键词
-
类别
资金
- NIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases) [N01-AR-700015]
- Clinical and Translational Science from Albert Einstein College of Medicine [3 UL1 TR00008605S1, UL1 RR025750]
- Indiana University [TR000006]
- University of Washington [1 UL1-RR025014-01, UL1 TR000423]
- Clinical and Translational Science Collaborative of Cleveland [UL1 TR000439]
- Dahms Clinical Research Unit at Case Medical Center
- Novartis
- Janssen
- Genentech
- UCB
- Amgen
Objective. To assess the efficacy and safety of rilonacept, an interleukin-1 inhibitor, in a randomized, double-blind, placebo-controlled trial. Methods. An initial 4-week double-blind placebo phase was incorporated into a 24-week randomized multicenter design, followed by an open-label phase. Seventy-one children who had active arthritis in > 2 joints were randomized (1:1) to the 2 arms of the study. Patients in the rilonacept arm received rilonacept (loading dose 4.4 mg/kg followed by 2.2 mg/kg weekly, subcutaneously) beginning on day 0. Patients in the placebo arm received placebo for 4 weeks followed by a loading dose of rilonacept at week 4 followed by weekly maintenance doses. The primary end point was time to response, using the adapted American College of Rheumatology Pediatric 30 criteria coupled with the absence of fever and taper of the dosage of systemic corticosteroids, using prespecified criteria. Results. The time to response was shorter in the rilonacept arm than in the placebo arm (chi(2) = 7.235, P = 0.007). The secondary analysis, which used the same response criteria, showed that 20 (57%) of 35 patients in the rilonacept arm had a response at week 4 compared with 9 (27%) of 33 patients in the placebo arm (P = 0.016). Exacerbation of systemic juvenile idiopathic arthritis (JIA) was the most common severe adverse event. More patients in the rilonacept arm had elevated liver transaminase levels (including levels more than 3 times the upper limit of normal) compared with those in the placebo arm. Adverse events were similar in the 2 arms of the study. Conclusion. Rilonacept was generally well tolerated and demonstrated efficacy in active systemic JIA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据